Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study
- 1 August 2011
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 378 (9792), 667-675
- https://doi.org/10.1016/s0140-6736(11)61219-1
Abstract
No abstract availableKeywords
Funding Information
- Cytokinetics
This publication has 20 references indexed in Scilit:
- Cardiac inotropes: current agents and future directionsEuropean Heart Journal, 2011
- Discovery of Omecamtiv Mecarbil the First, Selective, Small Molecule Activator of Cardiac MyosinACS Medicinal Chemistry Letters, 2010
- Improvement of Cardiac Function by a Cardiac Myosin Activator in Conscious Dogs With Systolic Heart FailureCirculation: Heart Failure, 2010
- Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondHeart Failure Reviews, 2009
- Effects of Cardiac Myosin Isoform Variation on Myofilament Function and Crossbridge Kinetics in Transgenic RabbitsCirculation: Heart Failure, 2009
- A novel approach to improve cardiac performance: cardiac myosin activatorsHeart Failure Reviews, 2009
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)European Heart Journal, 2008
- Performance of Phonoelectrocardiographic Left Ventricular Systolic Time Intervals and B-Type Natriuretic Peptide Levels in the Diagnosis of Left Ventricular DysfunctionAnnals of Noninvasive Electrocardiology, 2007
- A critical review of the systolic time intervals.Circulation, 1977
- Systolic Time Intervals in Heart Failure in ManCirculation, 1968